CTOs on the Move

Biomea Fusion

www.biomeafusion.com

 
Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Biomea Fusion raised $56M on 01/06/2021

Similar Companies

Critical Path Services

Critical Path Services is a Garnet Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

MBL

MBL is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Morphogenesis

Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.